117 related articles for article (PubMed ID: 4483535)
1. Determination of physiologic availability of commercial phenylbutazone preparations.
Chiou WL
J Clin Pharmacol New Drugs; 1972 Jul; 12(7):296-300. PubMed ID: 4483535
[No Abstract] [Full Text] [Related]
2. The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters.
Withey RJ; Feng H; Cook D; Van Petten GR; Lettau HF
J Clin Pharmacol New Drugs; 1971; 11(3):187-96. PubMed ID: 5211352
[No Abstract] [Full Text] [Related]
3. The physiologic availability of solid dosage forms of phenylbutazone. I. In vivo physiologic availability and pharmacologic considerations.
Van Petten GR; Feng H; Withey RJ; Lettau HF
J Clin Pharmacol New Drugs; 1971; 11(3):177-86. PubMed ID: 5211351
[No Abstract] [Full Text] [Related]
4. Biopharmaceutical assessment of phenylbutazone and indomethacin preparations.
Turakka H; Airaksinen MM
Ann Clin Res; 1974; 6(0):suppl 11:34-43. PubMed ID: 4855463
[No Abstract] [Full Text] [Related]
5. Canadian experience.
Cook D
Pharmacology; 1972; 8(1):190-8. PubMed ID: 4644648
[No Abstract] [Full Text] [Related]
6. Biopharmaceutics of drugs administered in lipid-containing dosage forms. I. GI absorption of griseofulvin from an oil-in-water emulsion in the rat.
Carrigan PJ; Bates TR
J Pharm Sci; 1973 Sep; 62(9):1476-9. PubMed ID: 4743096
[No Abstract] [Full Text] [Related]
7. Phenylbutazone.
Leeson LJ
Pharmacology; 1972; 8(1):154-63. PubMed ID: 4644645
[No Abstract] [Full Text] [Related]
8. Comparative bioavailabilities from truncated blood level curves.
Lovering EG; McGilveray IJ; McMillan I; Tostowaryk W
J Pharm Sci; 1975 Sep; 64(9):1521-4. PubMed ID: 1185570
[TBL] [Abstract][Full Text] [Related]
9. Role of drug metabolism in drug research and development: pharmaceutical chemistry aspects.
Heimlich KR
J Pharm Sci; 1972 Oct; 61(10):1686-9. PubMed ID: 5072432
[No Abstract] [Full Text] [Related]
10. Proceedings: The comparison of the bioavailabilities of commercial nitrofurantoin tablets.
McGilveray IJ; Mattok GL; Hossie RD
Rev Can Biol; 1973; 32():Suppl:99-106. PubMed ID: 4777608
[No Abstract] [Full Text] [Related]
11. [Evaluation of the biologic availability of drugs under clinical conditions].
Cepelák V; Mayer O; Cepeláková H; Vitous J; Petrlík M
Cesk Farm; 1977 Mar; 26(2):59-64. PubMed ID: 577192
[No Abstract] [Full Text] [Related]
12. Plasma half-life of phenylbutazone in patients with impaired liver function.
Hvidberg EF; Andreasen PB; Ranek L
Clin Pharmacol Ther; 1974 Feb; 15(2):171-7. PubMed ID: 4855829
[No Abstract] [Full Text] [Related]
13. Oxyphenbutazone and phenylbutazone determination in plasma and urine by GLC.
Bruce RB; Maynard WR; Dunning LK
J Pharm Sci; 1974 Mar; 63(3):446-8. PubMed ID: 4820382
[No Abstract] [Full Text] [Related]
14. Effect of oral contraceptives on plasma clearance.
Carter DE; Bressler R; Hughes MR; Haussler MR; Christian D; Heine MW
Clin Pharmacol Ther; 1975 Dec; 18(6):700-7. PubMed ID: 173489
[TBL] [Abstract][Full Text] [Related]
15. Phenylbutazone: factors influencing plasma concentrations.
Davies DS
J Int Med Res; 1977; 5 Suppl 2():15-9. PubMed ID: 913869
[TBL] [Abstract][Full Text] [Related]
16. Effect of lead exposure on plasma phenylbutazone levels in rats.
Basu N; Kulsreshtha T
Indian J Physiol Pharmacol; 1994 Jan; 38(1):61-2. PubMed ID: 8132249
[TBL] [Abstract][Full Text] [Related]
17. Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors.
Andreasen PB; Froland A; Skovsted L; Andersen SA; Hauge M
Acta Med Scand; 1973 Jun; 193(6):561-4. PubMed ID: 4738705
[No Abstract] [Full Text] [Related]
18. [Biological availability of drugs].
Holovkin VO
Farm Zh; 1979; (2):20-5. PubMed ID: 456507
[No Abstract] [Full Text] [Related]
19. Evaluation of dosage forms. IV. Studies on commercial phenylbutazone tablet dosage forms.
Razdan B; Paradkar AR
Drug Dev Ind Pharm; 1998 Jul; 24(7):599-604. PubMed ID: 9876503
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of bumadizone-, phenylbutazone- and oxyphenbutazone-plasma levels after a single oral dose of phenylbutazone and of bumadizone, respectively (author's transl)].
Spahn H; Mutschler E; Geissler HE; Faust-Tinnefeldt G
Arzneimittelforschung; 1981; 31(3):499-503. PubMed ID: 6894380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
